Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Evoke Pharma stock | $2.93

Own Evoke Pharma stock in just a few minutes.

Fact checked

Evoke Pharma, Inc is a drug manufacturers-specialty & generic business based in the US. Evoke Pharma shares (EVOK) are listed on the NASDAQ and all prices are listed in US Dollars. Evoke Pharma employs 5 staff and has a market cap (total outstanding shares value) of USD$74.2 million.

How to buy shares in Evoke Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Evoke Pharma. Find the stock by name or ticker symbol: EVOK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Evoke Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.93, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Evoke Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Evoke Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Evoke Pharma share price

Use our graph to track the performance of EVOK stocks over time.

Evoke Pharma shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$2.93
52-week rangeUSD$0.79 - USD$6.063
50-day moving average USD$3.0955
200-day moving average USD$3.931
Wall St. target priceUSD$9.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.395

Buy Evoke Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Evoke Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Evoke Pharma price performance over time

Historical closes compared with the close of $2.93 from 2020-12-09

1 week (2021-01-15) 5.40%
1 month (2020-12-23) 2.45%
3 months (2020-10-22) -36.99%
6 months (2020-07-22) -19.51%
1 year (2020-01-22) 100.68%
2 years (2019-01-22) 4.83%
3 years (2018-01-22) 8.92%
5 years (2016-01-22) 3.23

Evoke Pharma financials

Gross profit TTM USD$0
Return on assets TTM -108.88%
Return on equity TTM -757.28%
Profit margin 0%
Book value $0.119
Market capitalisation USD$74.2 million

TTM: trailing 12 months

Shorting Evoke Pharma shares

There are currently 469,245 Evoke Pharma shares held short by investors – that's known as Evoke Pharma's "short interest". This figure is 37.5% up from 341,315 last month.

There are a few different ways that this level of interest in shorting Evoke Pharma shares can be evaluated.

Evoke Pharma's "short interest ratio" (SIR)

Evoke Pharma's "short interest ratio" (SIR) is the quantity of Evoke Pharma shares currently shorted divided by the average quantity of Evoke Pharma shares traded daily (recently around 249598.40425532). Evoke Pharma's SIR currently stands at 1.88. In other words for every 100,000 Evoke Pharma shares traded daily on the market, roughly 1880 shares are currently held short.

However Evoke Pharma's short interest can also be evaluated against the total number of Evoke Pharma shares, or, against the total number of tradable Evoke Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evoke Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Evoke Pharma shares in existence, roughly 20 shares are currently held short) or 0.0185% of the tradable shares (for every 100,000 tradable Evoke Pharma shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Evoke Pharma.

Find out more about how you can short Evoke Pharma stock.

Evoke Pharma share dividends

We're not expecting Evoke Pharma to pay a dividend over the next 12 months.

Evoke Pharma share price volatility

Over the last 12 months, Evoke Pharma's shares have ranged in value from as little as $0.79 up to $6.063. A popular way to gauge a stock's volatility is its "beta".

EVOK.US volatility(beta: 1.49)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evoke Pharma's is 1.4924. This would suggest that Evoke Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Evoke Pharma overview

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site